Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + erlotinib + gefitinib + osimertinib
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of four EGFR tyrosine kinase inhibitors (TKIs) used in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). The combination includes first-generation (erlotinib, gefitinib), second-generation (afatinib), and third-generation (osimertinib) EGFR-TKIs. This preemptive combination approach aims to overcome resistance mechanisms that develop during treatment with single agents. Research suggests that combinations of these TKIs may dramatically increase progression-free survival (PFS) compared to monotherapy by targeting different resistance mechanisms simultaneously.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on afatinib + erlotinib + gefitinib + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + erlotinib + gefitinib + osimertinib.